P latelet-activating factor (PAF), 1-O-alkyl-2-acetyl-snglycero-3-phosphocholine, is an unusual phospholipid that can activate neutrophils, platelets, and monocytes at nanomolar concentrations. 12 In addition, it is a potent vasoactive and pro-inflammatory agent, causing hypotension 3 and anaphylaxis when infused into experimental animals, 4 and inflammation and edema when injected into the skin of humans. 5 Production of PAF has been demonstrated in most cells involved in the inflammatory response, including platelets, neutrophils, monocytes, tissue macrcphages, and basophils, 2 ' s-™ suggesting that this potent phospholipid may mediate inflammatory and immunologic responses.
In cultured endothelial cells derived from human umbilical vein, we have shown that the cells produce PAF in response to soluble agonists that are known to be involved in inflammatory and coagulation responses (e.g., throm-- 14 In addition, in umbilical vein endothelial cells, the production of PAF occurs In response to the same agonists that cause synthesis and release of prostacyclin (PGIJ, a potent vasodilator and inhibitor of platelet activation. Furthermore, the production of PAF is tightly linked to other responses of the endothelial cell, including increased adhesiveness for neutrophils. 1314 These findings suggest that the production of PAF and PGI 2 are components of a complex and highly regulated group of activities of endothelium that may be important in inflammation and vascular homeostasis, including regulation of endothelial-inf lammatory cell interactions. If this co-ordinated production of potent pro-inflammatory and vasoactive substances, which generally have opposing effects, occurs in endothelium in a variety of vascular beds, it would strengthen the hypothesis that the production of PAF is an important component of endothelial responses in physiologic states, in inflammation, and potentially in syndromes of vascular injury, such as atherosclerosis. However, which vascular beds and vascular components have the capacity to produce PAF, and what physiologic or pathologic agonists stimulate that production, are not known.
In this paper, we present evidence that bovine endothelial cells from a variety of vascular beds produce PAF in response to inflammatory and vasoactive mediators. As we have reported for human umbilical vein endothelial cells, 11 " 15 PAF accumulates in response to specific agonists that are known to have receptor-mediated actions.
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However, PAF production in bovine endothelial cells occurs in response to stimulation with agonists different than those that cause PAF production in human umbilical vein endothelial cells. The PAF produced by bovine endothelium remains cell-associated and is not released into the surrounding medium. Moreover, our studies provide further evidence that this production is a part of a generalized endothelial response that includes release of arachidonic acid metabolites, suggesting that production of PAF is an important component of a complex cellular response.
Methods Materials
PAF (>99% pure) was purchased from Avanti Polar Lipids, Inc. (Birmingham, AL). Calcium ionophore A23187, substance P, angiotensin I, angiotensin II, vasopressin, bradykinin, lipoporysaccharide (E. coli serotype 055:b5), /V-formyl-methionyl-leucyl-phenylalanine (FMLP), histamine, bovine thrombin, and adenosine triphosphate (ATP) were purchased from Sigma (St. Louis, MO).
3 H-acetate (3.4 Ci/mmol) and 3 H-alkyl PAF (44 Ci/mmol) were purchased from New England Nuclear (Boston, MA). Purified human thrombin was a gift from George Broze, Washington University, St. Louis, MO. Medium 199 and antibiotic solutions were from KC Biological (Lenexa, KS). Leukctriene C 4 (LTC 4 ) was provided by Joshua Rokach (MerckFrosst, Montreal, Canada). The PAF inhibitor, L-652,731, was provided by John Chabala (Merck Sharp and Dohme, Rahway, NJ). Purified PAF acetylhydrolase was prepared by Diana Stafforini as described. 16 
Endothelial Cell Culture

Aorta, Pulmonary Artery, and Inferior Vena Cava
Bovine vascular segments were obtained immediately after slaughter. The vessels were ligated, dissected free, and transported to the laboratory in iced saline. In sterile fashion, 16-gauge catheters were inserted into the vessel near each ligature. The lumen of the vessel was rinsed with sterile Hank's balanced salt solution (HBSS) until free of blood and was then infused with 25 ml of a 0.2% collagenase solution (Cooper Biomedical, Malvern, PA) in HBSS. The vessel was incubated in a waterbath (37°C) for 15 minutes with frequent rotation. The collagenase solution was withdrawn from the vessel, and the endothelial cells were recovered by centrifugation. They were resuspended in medium 199 containing 20% fetal bovine serum (Hyclone Laboratories, Logan, UT), 100 units/ml penicillin, and 100 Mg/ml streptomycin, and they were then plated onto gelatin-coated 35 mm Petri dishes (Corning Glass Works, Corning, NY). After incubation at 37°C for 4 hours in 5% COa/95% air, nonadherent cells were aspirated, the medium was replaced, and the culture dishes were returned to the incubator. Thereafter, the medium was changed every 3 days.
Bovine Coronary Vasculature
Bovine hearts were obtained at the time of slaughter and the aorta was ligated. The left main coronary artery was exposed and cannulated using a sterile plastic catheter.
Approximately 500 ml of sterile HBSS was infused through the cannula to remove blood. Approximately 15 ml of sterile glass beads (300 /xm diameter) suspended in HBSS was injected to occlude the coronary microcirculation. Then, 30 ml of 0.2% collagenase was instilled, and the heart was immersed in a water bath (37°C) for 20 minutes. The collagenase solution then was aspirated, and the endothelial cells were recovered and cultured as described here.
Characterization of Cultured Endothelial Cells
The cells were confluent within 5 to 8 days, and only tightly confluent cells in primary culture were used for these experiments. At confluence there were 1.04 ± 0.07 x 10 6 cells per 35 mm dish (n = 10), and fibroblasts, smooth muscle cells, and other cells constituted less than 1% of the cell population. All cell cultures were examined at confluence by phase contrast microscopy, and cells were identified as endothelial by their typical morphology, which was a contact-inhibited, tightly-apposed, cobblestone appearance. The cells were also identified as endothelial cells by staining for von Willebrand factor (vWF) by indirect immunofluorescence, the presence of angiotensin-converting enzyme (ACE) activity, and the ability to take up acetylated low density lipoprotein (LDL). 17 ACE activity was measured by the method of Ryan et al., 18 with the use of the radiolabeled substrate 3 H-benzoyl-phenylalanine-alanine-proline (Ventrex Laboratories, Portland, ME).
Assay of Platelet-Activating Factor Production
Production of PAF was measured by incorporation of 3 H-acetate into PAF by a modification 11 -12 of the method described by Mueller et al. 19 This has been shown to be an accurate method of measuring PAF accumulation in endothelial cells 11~15 and in rat neutrophils, where the measurement of 3 H-acetate incorporation correlated precisely with quantitation by gas chromatography-mass spectroscopy under a variety of conditions. 20 The medium was removed from confluent monolayers and replaced with 1 ml of HBSS/10 mM HEPES (pH 7.4) containing 25 fid of carrier-free 3 H-acetate and the appropriate concentration of agonist. The incubations were performed at 25°C and were stopped at the indicated times by the addition of 0.5 ml of 50 mM acetic acid in methanol. Control incubations were performed identically but with no agonist. In the case of whole-tissue preparations, incubations were carried out in the wells of the plastic template just as in the culture dishes. After the addition of the acidified methanol, the cells were scraped from the surface of the culture dish or from the surface of the vessel; 50 fig of unlabeled PAF was added as a carrier, and the lipids were extracted by the method of Bligh and Dyer. 21 The sample was dried under N 2 , it was redissolved in a known volume of chloroform/ methanol (9:1), and 10% was removed and used to determine the total radioactivity present. The remaining lipids were then separated by thin-layer chromatography (TLC) on precoated plates of silica gel 60 (Merck, Darmstadt, FRG) in CHCIa/MeOH/glacial acetic add/water (50:25:8: 4). The silica was scraped in fractions corresponding to authentic standards from the entire lane of a TLC plate, and the radioactivity in each fraction was determined by liquid scintillation spectrometry. The results for the fraction containing a standard of authentic PAF were expessed as a percentage of the total radioactivity in the lane. This value was multiplied by the original determination of total radioactivity in the lipid extract to yield a dpm of 3 H-acetate incorporated into PAF. Control extractions performed with authentic radiolabeled PAF routinely give > 90% recovery using this technique.
Assay of In Situ Vascular Endothellal Cells
Bovine pulmonary arteries and aortas were harvested and were sectioned lengthwise. The resulting segment of vessel wall was placed in a plastic template, luminal surface upward, so that a 35 mm diameter well was formed with an In situ layer of endothelium constituting the bottom of the well. Care was taken not to injure the endothelial surface. The wells were washed several times with HBSS to remove any remaining blood. Incubations were carried out in these wells just as in culture dishes, and the endothelial cells were harvested by gentle scraping with a scalpel blade. In the case of vessels denuded of endothelium by collagenase treatment, the resulting vascular wall was exposed to the agonist solution and the exposed tissue was harvested by vigorous scraping. In situ endothelial cells on ex vivo vascular segments were examined by electron microscopy. Tissues were fixed overnight in Karnovsky's solution and then washed with a buffered salt solution. The tissues were dehydrated to critical point dryness, were coated with atomic gold by vacuum evaporation, and were examined in a JEOL-JSM35 scanning electron microscope, as described previously.
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Identification of Radiolabeled Product as Authentic Platelet-Activating Factor
The radiolabeled lipid was shown to be authentic PAF by using the radiolabeled product from two separate types of endothelial cells (aortic and pulmonary artery) treated with two ditferent agonists (10~5 M calcium ionophore and 10" 8 M bradykinin). In each case, the following results confirmed the identity of the product: 1) comigration with authentic PAF on TLC; 2) an identical elution volume on high performance liquid chromatography; 3) degradation of more than 95% of the radiolabeled product by phospholipase A2 from Crotalus adamantus,' 12 confirming that 3 Hacetate had been incorporated at the sn-2 position of the phospholipid. In all cases, the radioactivity released after phospholipase Aj treatment partitioned completely into the aqueous phase of an acidified extraction mixture. This result and the chromatographic mobility demonstrated that the radioactive molecule was a short-chain organic acid; 4) degradation of less than 5% of the endothelial cell product (n = 2) with phospholipase A, from Rhizopus arrhizus™ consistent with an ether linkage at the sn-1 position; 5) complete (>90%) degradation by PAF acetylhydrolase purified from human plasma 16 (these results confirmed that the radioactive organic acid at the sn-2 position was acetate, since this enzyme exhibits marked specificity for acetate 16 ); 6) typical bioactivity causing aggregation of human platelets and increased adherence of human neutrophils to gelatin-coated plastic dishes.
Bioactivity and Determination of Specific Radioactivity of Endothellal Cell Platelet-Activating Factor
The bioactivity of the endothelial cell PAF was determined using two criteria: the ability to cause aggregation of human platelets, and the ability to cause increased adherence of human neutrophils to gelatin-coated plastic dishes. To assess the ability of the endothelial cell PAF to cause platelet aggregation, endothelial cells were incubated in the presence of 25 /JLC\ of 3 H-acetate and an agonist. The incubations were terminated, and the lipids were extracted and separated as described in the assay of PAF production (above) without the addition of carrier PAF. The TLC fraction that comig rated with authentic PAF was identified; PAF was extracted from this fraction by the method of Bligh and Dyer; 21 then the organic phase was removed and evaporated under nitrogen. This was solubilized in 50 fi\ of 0.9% NaCI -)-0.5% bovine serum albumin (BSA) and was assayed for the ability to cause aggregation of human platelets as described. 15 The amount of PAF in the endothelial cell extracts was determined by comparing the maximal deflection of the aggregation wave to that produced by authentic PAF standards. Control incubations (no agonist) demonstrated no bioactivity. The contents of the aggregation cuvettes were then transferred to scintillation vials and solubilized with 1 ml of 1M ammonium hydroxide, and the amount of radioactivity present in the aggregation assay was determined by liquid scintillation counting. The specific radioactivity of the PAF produced by the stimulated endothelial cells was determined by dividing the radioactivity in the sample by the amount of PAF, as determined by platelet aggregometry. The total amount of PAF in stimulated endothelial cells was determined by correcting the amount in the platelet aggregometry assay for percentage recovery. Percentage recovery was determined by adding a known amount of authentic 3 H-alkyl PAF to dishes of unstimulated endothelial cells at the time of extraction. Extractions and separations were performed identically and the amount of radiolabeled standard recovered was measured to determine the percentage recovery.
In parallel studies, the endothelial cell PAF was extracted in identical fashion and treated with purified PAF acetylhydrolase 16 for 30 minutes. Endothelial cell PAF treated in this fashion caused no detectable platelet aggregation. The endothelial cell product from 10 6 cells was exposed to 0.042 units of PAF acetylhydrolase for 30 minutes in 50 ix\ of 0.9% NaCI. This amount of enzyme could hydrolyze 42 nmol of PAF per hour at saturating PAF concentrations. 16 The bioactivity of the endothelial cell product was also measured by using adherence of 111 indium-labeled human neutrophils to gelatin-coated plastic culture dishes, which we have developed as a sensitive assay for PAF bioactivity that is comparable to bioactivity measured by neutrophil or platelet aggregation (Zimmerman GA et al., unpublished data). Adherence induced by authentic PAF is prevented by the inclusion of a variety of specific PAF receptor antagonists (e.g., kadsurenone, L652.731) and by previous hydrolysis of the acetate ester at the sn-2 position. Neutrophil adherence induced by the PAF isolated from endotheiial cells was compared to a standard curve of neutrophil adherence in response to authentic PAF and was determined in the presence and absence of the PAF receptor antagonist, L652.731. This compound completely blocked the increased adherence induced by the purified endotheiial product (n = 4). In parallel incubations without the addition of 3 H-acetate to the stimulation buffer, endotheiial cell lipids were extracted without carrier PAF and were separated in the high pressure liquid chromatographic system of Blank and Snyder. 22 Control separations in this system using authentic radiolabeled PAF demonstrated more than 90% recovery. The fractions that eluted in the same volume as authentic PAF were collected and assayed for bioactivity; in each case, this material demonstrated typical bioactivity that was inhibited by the addition of L652.731 (Merck), a specific PAF inhibitor.
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Labeling and Stimulation of Endotheiial Cells with Exogenous
H-Alkyl Platelet-Activating Factor
To assess the ability of stimulated endotheiial cells to degrade PAF, confluent primary cultures of bovine pulmonary artery or aortic endotheiial cells (10 8 cells per dish) were labeled with 3 H-alkyl PAF in medium 199 + 1 mg/ml of fatty acid-free BSA containing 30 nM PAF (6 /xCi/nmol) for 90 minutes at 37°C. The labeling medium was removed and the monolayers were washed twice with HBSS. The cells then were exposed to buffer (HBSS, pH 7.4) containing bradykinin (10" 8 M), A23187 (10" 5 M), or ATP (10" 3 M). Control incubations were performed identically, but in the absence of agonists. At 0,1,5, and 10 minutes the incubations were terminated by the addition of acidified methanol to the incubation buffer. The endotheiial cell lipids were extracted by the method of Bligh and Dyer. 21 Lipids were separated by TLC and the 3 H-alkyl PAF content was quantitated as described above.
Assay of Platelet-Activating Factor Acetylhydrolase Activity
Endotheiial cell PAF acetylhydrolase activity was measured as described. 16 Briefly, endotheiial cells were incubated with potential agonists or control buffer; after 0,1, 2, and 5 minutes, the cells were washed three times with icecold HBSS and then scraped into 0.5 ml of 0.1 M HEPES (pH 7.2). The cells were disrupted by sonication for 15 seconds at 100 W, 10 fi\ of this solution was incubated with 80 /iM of 3 H-acetyl PAF (25 000 dpm/nmol) in a final volume of 50 ix\ at 37°C for 30 minutes. The incubation mixture was then placed on a disposable, reverse-phase column (SEP-PAK C18, Waters Associates, Milford, MA), and the column was eluted with 3 ml of 0.1 M sodium acetate; the eluant was collected and the amount of radiolabeled acetate was determined by scintillation spectroscopy.
ftadlolmmunoassay of Prostacyclln
Production of prostacyclin was determined by quantitation of 6-keto PGF 1a , the stable metabolite of PGI 2 , as described previously. 12 Confluent cell monolayers were exposed to 1 ml of HBSS/10 mM HEPES with or without an agonist. At the indicated times, 100 /xl aliquots were removed for quantitation, and the volume of the assay buffer was maintained by the addition of an equal volume of a buffer solution containing the appropriate agonist.
Statistical Methods
Student's f test (two-tailed) was used to determine the statistical significance.
Results
Endothellum from Diverse Vascular Beds Produces Platelet-Activating Factor
Initial studies were performed with endotheiial cells cultured from bovine aorta, pulmonary artery, coronary vasculature, and vena cava. When these cells were stimulated with calcium ionophore A23187 in the presence of 3 Hacetate, the radiolabel was detected in PAF within 10 minutes (Table 1 ). In addition, cultured endotheiial cells from each of these four vascular beds were stimulated with ATP (10~3 M), and PAF accumulated again within 10 minutes (Table 1 ). There was variability in the amount of PAF that accumulated in stimulated cells from different isolates; however, stimulated PAF accumulation in endotheiial cells from aorta, pulmonary artery, and coronary artery was more than ten times the production from buffer-treated controls in every experiment (n = 15), and the results were highly consistent within each experiment (isolate). The amount of PAF produced by endotheiial cells from the inferior vena cava in response to the same agonists was less than in the arterial endothelium, but was always more than twice the production in controls incubated in parallel. 6 cells per dish) were stimulated with the indicated agonist for 10 minutes at room temperature, PAF synthesis was determined as the incorporation of 3 H-acetate into PAF. *p < 0.01 compared to control, t P < 0.02 compared to control. PAF = platelet-activating factor, ATP = adenosine triphosphate.
PLATELET-ACTIVATING FACTOR PRODUCTION BY ENDOTHELIUM Whatley et al. 325
To investigate this apparent difference between endotheiial cells of arterial and venous origin and to eliminate any difference between endothelium from different animals, endotheiial cells from aorta, pulmonary artery, and inferior vena cava were isolated from the same animal, were cultured identically, and were stimulated in parallel with calcium ionophore A23187, ATP, and several potential physiologic agonists ( Table 2) . As before, stimulation of endotheiial cells from each vascular source resulted in the accumulation of PAF, and the magnitude of the response in endotheiial cells from aorta and pulmonary artery was greater than that in endotheiial cells from the inferior vena cava.
Production of PAF in response to both calcium ionophore and ATP confirmed that endotheiial cells from all four vascular sources have the capacity to produce PAF (Tables 1 and 2 ). Moreover, preliminary studies suggested that endotheiial cells from these vessels produced PAF in response to bradykinin and angiotensin II ( Table 2) . Consequently, we intensively investigated the ability of pulmonary artery and aortic endotheiial cells to produce PAF in response to known inflammatory mediators and vasoactive substances. Cultured pulmonary artery endotheiial cells produced PAF in response to bradykinin and angiotensin II. A number of other substances, including thrombin and histamine, which are known to cause PAF production in cultured human umbilical vein endotheiial cells, 11 ' 12 did not simulate these cells (Table 3 ). The production of PAF in response to bradykinin was time-dependent, with maximal production occurring within 20 minutes ( Figure 1A ). Separate assays of the supernatant and monolayer demonstrated that the PAF was completely cell-associated, with no levels above background detected in the supernatant fraction. Bradykinin-induced production of PAF was concentration-dependent, with maximal accumulation occurring at 10" 8 M ( Figure 1B ). There was a significant decrease in PAF accumulation at higher concentrations of bradykinin, a phenomenon that has been observed for other actions of bradykinin on endotheiial cells, including release of prostaglandins.
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Like bradykinin, angiotensin II caused accumulation of PAF in a time-and concentration-dependent manner. Maximal accumulation occurred within 10 minutes and at 10" 5 M angiotensin II (data not shown). Again, all of the PAF was cell-associated. This response was specific for angiotensin II in that antiotensin I did not cause accumulation of PAF in two experiments in which monolayers from the same culture were stimulated with one or the other. As in the case of bradykinin, there was a reproducible descending limb of the concentration-response curve at concentrations of angiotensin II greater than 10~5 M.
To further characterize the ability of bovine endothelium to produce PAF, aortic endotheiial cells in culture were evaluated using the same techniques and panel of potential agonists as described above for pulmonary artery endotheiial cells. In addition to calcium ionophore and ATP, stimulation with bradykinin resulted in the accumulation of PAF in a time-and concentration-dependent fashion (Figures 1C and 1D) . Aortic endotheiial cells in culture also produced PAF in response to angiotensin II (10" 8 M), but not to angiotensin I (10" 8 M). A number of other potential agonists that did not induce PAF production in cultured aortic endotheiial cells were tested (Table 3) .
In addition to their response to calcium ionophore A23187 and ATP (Table 1) , endotheiial cells cultured from the coronary vasculature produced PAF after stimulation with bradykinin and angiotensin II. When cultured coronary endotheiial cells (10 8 per point) were stimulated for 10 minutes with bradykinin (lO^MJ^H-acetate was readily incorporated into PAF (6228 ± 1915 dpm vs. 205 ± 70 dpm, stimulated vs. control; mean ± SEM, n = 4; p < 0.01). In an identical assay, angiotensin II (10" 6 M) also resulted in PAF accumulation (1360 ± 373 vs. 205 ± 70, stimulated vs. control; mean ± SEM, n = 4; p < 0.01). Cultured endotheiial cells from the inferior vena cava were stimulated with bradykinin (10" 8 M) and angiotensin II (10" 8 M), and PAF accumulated in stimulated cells similar to controls (data not shown); however, as noted above, levels of accumulation were less than that in endotheiial cells of arterial origin (Table 2) .
Finally, as further proof that endotheiial cells from diverse vascular sources have the capacity to produce PAF when appropriately stimulated, bovine renal artery endotheiial cells were cultured and stimulated with two representative agonists, calcium ionophore (10~5 M) and bradykinin (10" 8 M) . Like endotheiial cells from other vessels, renal artery endotheiial cells accumulated PAF when stimulated for 10 minutes with calcium ionophore (14 228 dpm) or bradykinin (17 922 dpm) (mean of two determinations, control = 131 dpm).
Measurement of Specific Radioactivity of Endotheiial Cell Platelet-Activating Factor
To assess whether the radiolabeling assay provided an accurate reflection of PAF accumulated by various endo- Values are the mean incorporation of label into PAF in two separate dishes (dpm). Endotheiial cells were harvested from a single animal and cultured identically. At confluence, cultured cells (10* cells per dish) were stimulated with the indicated agonist for 10 minutes at room temperature in the presence of 3 H-acetate. AT-II = angiotensin II, AT-I = angiotensin I, PAF = platelet-activating factor, ATP = adenosine triphosphate. thelial cells in response to different agonists, we measured the specific radioactivity of the 3 H-acetyl PAF produced under a variety of conditions. These experiments were performed with five different isolates and with two bioassays, platelet aggregation and neutrophil adherence. With cultured aortic endothelial cells, the values obtained using the platelet aggregation assay were: calcium ionophore (10-5 M), 1.8 Ci/mmol; bradykinin (10-6 M), 1.5 Ci/mmol; ATP (10-3 M), 1.3 Ci/mmol; and angiotensin II (10" 6 M), 1.3 Ci/mmol. We then measured production by pulmonary artery and coronary vascular endothelial cells in response to bradykinin (10" 6 M) and obtained values of 1.2 Ci/mmol (pulmonary artery) and 1.6 Ci/mmol (coronary artery). Thus, cells from different beds yielded similar values in response to bradykinin, and aortic endothelial cells gave similar results when stimulated by different agonists. These results were confirmed in the neutrophil adherence assay where aortic and pulmonary artery endothelial cells were stimulated with either bradykinin (10" 8 M) or calcium ionophore (10~5 M); using this assay, the specific radioactivity was determined to be 1.1 ± 0.3 Ci/mmol (mean ± SEM; n = 4). From these data, we conclude that the val-ues obtained by the radiolabeled tracer method yield a quantitatively accurate result.
Cause of Platelet-Activating Factor Accumulation
Accumulation of PAF in stimulated endothelium could occur as a result of stimulated synthesis or a stimulationinduced decrease in the activity of cellular PAF acetylhydrolase, the enzyme that degrades PAF. To assess whether the observed accumulation was a result of stimulated synthesis and not a decrease in degradation of constitutively synthesized PAF, endothelial cells were labeled with exogenous 3 H-alkyl PAF and were exposed to buffer solutions containing calcium ionophore (10~5 M), bradykinin (10" 8 M), ATP (10" 3 M), or buffer alone. At 0, 1, 5, and 10 minutes, the incubations were stopped and the amount of 3 H-alkyl PAF remaining was determined. Pulmonary artery endothelial cells exposed to buffer alone demonstrated a loss of labeled PAF over 10 minutes, from 3188 ± 309 cpm to 2790 ± 189 cpm (mean ± SEM; n = 2). The 3 Halkyl PAF content of endothelial cells exposed to agonists also decreased during the 10-minute incubation and was not significantly different from control levels at each time. At 10 minutes, the 3 H-alkyl PAF content of cells stimulated with bradykinin was 2722 ± 434 cpm, for ATP 2768 ± 92 cpm, and for calcium ionophore 2881 ± 10 (mean ± SEM; n = 2). Identical results were obtained in an experiment using aortic endothelial cells stimulated with the same agonists. This evidence demonstrates that accumulation of PAF in stimulated cells is not due to a decrease in the activity of degradatory pathways.
To investigate this in a different fashion, we measured the activity of the PAF acetylhydrolase in pulmonary artery endothelial cells stimulated with calcium ionophore or ATP. PAF acetylhydrolase activity in the basal state was 58 ± 8 pmol/min/10 6 cells (mean ± SEM; n = 5), and there was no change in hydrolase activity during 5 minutes of stimulation. This strongly suggests that accumulation of PAF is a result of stimulated synthesis and not a decrease in degradation. PAF acetylhydrolase activity was also measured in aortic endothelial cells stimulated with bradykinin (10" 8 M). The activity in unstimulated cells was 96 ± 2 pmol/min/10 6 cells (mean ± SEM;n = 4), and there was no change in activity during 5 minutes of stimulation. As in the case of stimulation with ATP or calcium ionophore, bradykinin-induced PAF accumulation appears to be due to stimulation of synthesis rather than to a decrease in PAF degradation.
In Situ, Ex Vivo Endothelial Cells Produce Platelet-Activating Factor
To exclude the possibility that PAF production observed in cultured bovine endothelial cells was a response induced by the process of cell culture, we studied endothelial cells in situ on isolated strips of bovine pulmonary artery and aorta. These experiments were performed on freshly harvested vessels by using a plastic template. The vessels were carefully opened and secured in the device with the luminal surface upward, forming a well with a layer of intact endothelium at the bottom; assays were performed in these wells just as in culture dishes. The integrity of the endothelial layer was confirmed by electron microscopy of tissue used in this device ( Figure 2A) . As in cultured endothelial cells, accumulation of PAF occurred in in situ pulmonary artery endothelial cells in response to calcium ionophore (2693 dpm) and bradykinin (1200 dpm) compared to control wells (no agonist, 158 dpm). In these studies, whole vascular walls with underlying smooth muscle cells and connective tissue were used. Although accumulation of PAF by cultured endothelial cells suggested that these cells are the site of PAF production in intact vessels, we investigated whether the in situ endothelium was, in fact, the source of the production. The intimal surface of intact pulmonary artery strips was exposed to 0.2% collagenase, and removal of the endothelium was confirmed by examination of the tissues with electron microscopy ( Figure 2B ). Pulmonary artery segments from which the endothelium had been removed did not produce PAF in response to calcium ionophore or bradykinin, confirming the endothelial cell was the major site of production.
Production of PAF by in situ, ex vivo endothelial cells was similar to production by cultured endothelial cells. Accumulation of PAF occurred in response to stimulation with bradykinin in a time-and concentration-dependent fashion, with maximal accumulation occurring within 10 minutes ( Figure 3A) . As in cultured endothelial cells, all of the PAF was cell-associated; the addition of 30 mg/ml of fatty acid-free BSA to the incubation buffer did not cause release of PAF into the supernatant ( Figure 3A) . Similar results were found in in situ endothelial cells on isolated segments of bovine aorta (Figure 4) . In in situ pulmonary artery endothelial cells, maximal accumulation of PAF occurred at 10" 6 M bradykinin, a concentration 100-fold greater than observed in cultured cells ( Figure 3B ). This difference between in situ and cultured cells may arise from several factors; because the activity of ACE, which cleaves bradykinin as well as angiotensin I, is known to decrease in cultured cells compared to intact tissues, 2526 we measured this activity in both cultured pulmonary endothelial cells and in situ endothelium. The activity of ACE in in situ pulmonary artery endothelial cells was 39.8 units, while that of pulmonary artery cells grown in culture was 9.7 units;* this may contribute to the difference in the bradykinin concentration-response relationship in cultured, versus in situ, endothelial cells.
In a single experiment utilizing the same techniques, ex vivo, in situ endothelial cells on an isolated segment of human pulmonary artery from a normal cadaveric organ donor produced PAF (2343 dpm vs. 675 dpm, stimulated vs. control) when stimulated with calcium ionophore A23187 (10~5 M) for 10 minutes.
Production of PGI 2 In Pulmonary Artery Endothelial Cells
Production of 6-keto PGF 1a , the stable metabolite of PGI 2 , by cultured pulmonary artery endothelial cells oc-*ACE activity was measured by hydrolysis of 3 H-benzoyl pheala-pro by 10 6 cells and is expressed as first-order units where one unit Is that quantity of enzyme required to hydrolyze substrate at an initial rate of 1%/minute at 37°C.
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ARTERIOSCLEROSIS VOL Figure 2 . The microscopic appearance of the intimal surface of an ex vivo bovine pulmonary artery segment. A. A representative portion of a pulmonary artery used in a typical experiment was examined by scanning electron microscopy. The photomicrograph shown demonstrates an intact layer of endothelial cells and an absence of inflammatory cells, x 4000 B. A micrograph of bovine pulmonary artery that had been denuded of endothelial cells by collagenase treatment. Vessels treated in this fashion did not produce platelet-activating factor in response to stimulation with calcium ionophore A23187 or bradykinin. x 4000 curred in response to bradykinin and angiotensin II ( Figure  5 ). Production of PGI 2 by pulmonary artery endothelium in response to bradykinin has been reported previously. 27 We have previously reported that human umbilical vein endothelial cells produce both PGI 2 and PAF in response to thrombin. 12 Because bovine pulmonary artery endothelial cells did not produce PAF in response to thrombin (Table 3), we measured PGI 2 production in response to thrombin as a negative control for the association of the two responses. As reported by others, 28 production of PGI 2 also was not increased above control levels ( Figure 5 
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II, 6-keto PGF 1a accumulated rapidly in the supernatant for the first 5 to 10 minutes, with a slower increase thereafter, a time course that paralleled the production of PAF by those same agonists (compare Figure 5 to Figure 1A) .
Discussion
These studies demonstrate that cultured endothelial cells derived from bovine aorta, pulmonary artery, coro- 5 M A23187 (T), or thrombin 2U/ml (•) in a total volume of 1 ml. At the times indicated, 100 pi aliquots were removed and replaced with an equal volume of Incubation buffer. 6-keto PGF 1a , the stable metabolite of PGI 2 , was measured in each aliquot by RIA. Appropriate corrections were made for each dilution. An identical experiment using cultured aortic endothelial cells gave the same results.
nary vasculature, and inferior vena cava accumulate PAF in response to stimulation with calcium ionophore A23187, ATP, bradykinin, and angiotensin II. Our data strongly suggest that accumulation of PAF in response to stimulation is due to increased synthesis. In situ endothelial cells on isolated segments of aorta and pulmonary artery also accumulate PAF, which excludes the possibility that this response is an artifact of cell culture and strongly suggests that it occurs in vivo. Moreover, in intact vessels, we demonstrated that accumulation of PAF is a response of the endothelium, but not the subendothelium. These studies expand our previously reported findings of PAF production in human umbilical vein endothelial cells 11 " 15 to include synthesis by endothelial cells from large and small arteries and large veins. Our findings of PAF production by bovine endothelial cells demonstrate that PAF synthesis is not a species-specific or tissue-specific response unique to human umbilical vein endothelial cells. Camussi et al. 29 ' 30 have shown PAF production in whole-tissue models using immune-mediated vascular injury, and additional experiments suggest that the endothelium was the site of synthesis. We have clearly identified the endothelial cell as the site of production and have demonstrated accumulation of PAF by endothelial cells from diverse vascular beds. Moreover, we have shown that accumulation of PAF occurs in response to soluble mediators, including bradykinin and angiotensin II, which are known to be physiologically active.
The significance of our findings is derived from the potent biologic effects of PAF, 5 previous observations that it is produced when endothelial cells are activated by specific agonists, and evidence that it is involved in intercellular interactions between endothelial cells and other cells, such as neutrophils. 13 ' u Our current findings that endothelial cells and ex vivo endothelium from diverse vascular beds all accumulate PAF in response to mediators of inflammation and vasoactive substances support our hypothesis that this response is an important and general component of endothelial activation.
These studies demonstrate, in endothelial cells from diverse vascular sources (including in situ endothelium), that PAF remains cell-associated. This confirms and expands our previous observations in human umbilical vein endothelial cells that PAF synthesized in response to stimulation remains associated with the endothelial cell, and there Is little released into the surrounding medium.
11 ' 12 > u The physiologic or pathologic consequences of this are not known at present; accumulation of PAF in the endothelial cell may play a direct role in mediating the interactions of the endothelial cell with other vascular components. Alternatively, PAF may mediate intracellular events that indirectly affect vascular physiology. The endothelial cell is a reactive cell that is strategically located for mediating hemostatjc and inflammatory events, as it is the interface between Intravascuiar components such as inflammatory cells and the extravascular compartments. We speculate that the fact that endothelial-derived PAF remains associated with the cell is also consistent with this view, since its effects are limited to the relevant site of endothelial response rather than being disseminated in the circulation.
Similarly, the heterogeneity of the pattern of physiologic agonists, which stimulate PAF accumulation in different vascular beds, demonstrates that this is a selective or regulated response of endothelium, suggesting an important role in mediating physiologic or pathologic phenomena. For example, in these studies we showed PAF accumulation in aortic and pulmonary artery endothelial cells in response to angiotensin II, a response not seen in human umbilical vein endothelial cells; 15 likewise, cultured human umbilical vein endothelial cells produce PAF in response to histamine and thrombin, 11 ' 12 a response not seen in either bovine pulmonary artery or aortic endothelial cells. This selectivity was previously demonstrated for other responses of endothelial cells, such as PGI 2 synthesis. 28 ' 31 The mechanisms for this selectivity are not known, but they may include differences in the coupling of receptor-ligand binding to intracellular responses.
As we and others have previously shotan in human umbilical vein endothelial cells, bovine pulmonary artery endothelial cells release prostacyclin in response to the same agonists that we have shown here to also induce PAF accumulation.
12 -32 - 33 Pulmonary artery endothelial cells produced PAF and released prostacyclin in response to stimulation with either bradykinin or angiotensin II: stimulation with thrombin resulted in no PAF accumulation and no prostacyclin release, in dramatic contrast to human umbilical vein endothelial cells, which demonstrate synthesis of both lipids in response to stimulation with thrombin. 12 This coordinated production of powerful pro-inflammatory and vasoactive substances has several implications. First, it is consistent with the hypothesis put forward by Chllton et al. 3 4 3 5 that free arachidonlc acid and the lysophospholipid precursor of PAF have a common precursor, 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A single reaction catalyzed by a phospholipase As activity after stimulation of a cell may yield the intermediates for the production of various oxygenated arachidonate metabolites and PAF. There is strong support for such a mechanism in human and rat neutrophils. 20 ' M -M ' M Second, the production of PAF and PGI 2 by endothelial cells in response to common agonists initially seems paradoxical since some of their physiological effects are counteractive. For example, PAF activates platelets, 15 ' 37 while PGI 2 inhibits activation. 3138 In this case, we postulate that the coproduction of these compounds may represent a mechanism to influence and "fine tune" platelet function, since the two lipid autacoids have opposing actions, and PGI 2 is released, whereas PAF remains cell-associated. The finding that ATP stimulates PAF accumulation in endothelial cells is particularly interesting with respect to endothelial interactions with platelets because stimulated platelets release ATP and ADP; we found that ADP also stimulates PAF synthesis (Whatley, RE et al., unpublished data). If these induce PAF accumulation in endothelial cells in vivo, this may be a positive feedback mechanism for platelet aggregation and adhesion at the vascular wall.
In other respects, we postulate that the actions of PAF and PGI 2 may be complementary, not opposing, at the vessel wall. This is a particularly intriguing possibility in the Inflammatory response since PAF activates neutrophils and monocytes and causes increased vascular permeability, 5 while PGI 2 causes vasodilation. 31 ' M Of particular interest in this regard is the spectrum of agonists that stimulate PAF accumulation in endothelial cells from aorta and pulmonary artery (Table 2) . Bradykinin is a potent inflammatory mediator and vasodilator, 39 and the ability to induce PAF and PGI 2 production in endothelial cells may be a mechanism that mediates some of its pro-inflammatory or vasoactive properties. In some vascular beds, ATP functions as an extracellular agonist that is a potent vasodilator. 40 Similarly, angiotensin II is a potent vasoactive substance but, in contrast to bradykinin and ATP, it is a powerful vasoconstrictor. 41 The degradation of each of these substances is a property of the endothelial cell, 31 ' 42 -43 providing a mechanism to regulate their local concentrations. Although of undetermined significance at this time, it is intriguing that each of these substances also stimulates PAF accumulation and may thereby influence local vascular events. 44 
